Hemanto Onco CRO - Veeda Lifesciences

Hematology-Oncology Research Specialists

Hematological malignancies continue to demand more answers and there's a deep urgency for more effective treatments options. For over 15 years, our Hemato-Oncology research has contributed to some of the most impactful trials of this field. Today, we’ve evolved as an agile partner, leveraging advanced AI tools and patient registries to drive successful Phase I to III trials and support the entire lifecycle process

In-depth therapeutic expertise reducing
growing trial complexity

Experts in the field of Multiple Myeloma

Supported some of the most some of the most promising novel and emerging therapies

Supporting the Entire Lifecycle Process

From Pre-Clinical Trials to Late Phase Trials

Artificial Intelligence Enabled

Access to AI tools and patient registries to target recruitment sites, and minimize enrollment timelines

Trials

Patients

Global Sites

Countries

Rooted in years of therapeutic
insight and leadership

Every breakthrough in hematologic cancer care begins with a clear focus: the patient. We bring deep therapeutic insight and hands-on experience across a wide spectrum: from frontline and maintenance therapies to MRD-based strategies and intricate combination regimens. Our scientists have a rich experience in translating growing trial complexity into smart-adaptive designs, all guided by the goal of delivering better outcomes, faster. Whether it’s through adaptive protocols or decentralized models, we’ve helped sponsors accelerate the development of precision therapies for both broad and high-risk populations.